ALK and cancer: Out of this series of 270 patients with a definitive diagnosis of cancer, molecular testing was carried out on 142 patients, looking for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and PD-L1 mutations.